27
Participants
Start Date
November 12, 2021
Primary Completion Date
June 16, 2024
Study Completion Date
December 20, 2038
TAK-007
TAK-007 intravenous injection.
Chemotherapy Agents
Fludarabine and cyclophosphamide as per standard of care.
Columbia University Medical Center, New York
Montefiore Medical Center, The Bronx
Thomas Jefferson University Sidney Kimmer Cancer Center, Clinical Research Organization, Philadelphia
MedStar Georgetown University Medical Center, Washington D.C.
University of Virginia Comprehensive Cancer Center, Charlottesville
DUHS Duke Blood Cancer Center, Durham
Northside Hospital, Atlanta
Sylvester Comprehensive Cancer Center University of Miami Hospitals and Clinics, Miami
University of Alabama at Birmingham, Birmingham
University of Michigan Comprehensive Cancer Center, Ann Arbor
Northwestern Memorial Hospital, Chicago
University of Texas MD Anderson Cancer Center, Houston
Saint Davids South Austin Medical Center, Austin
Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Oregon Health and Science University, Portland
Lead Sponsor
Takeda
INDUSTRY